NASDAQ:ABIO ARCA biopharma - ABIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ARCA biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.03 -0.04 (-1.93%) (As of 03/28/2023 05:12 PM ET) Add Compare Share Share Today's Range$2.00▼$2.0950-Day Range$2.02▼$2.3452-Week Range$1.76▼$2.70Volume20,508 shsAverage Volume32,002 shsMarket Capitalization$29.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About ARCA biopharma (NASDAQ:ABIO) StockARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.Read More Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABIO Stock News HeadlinesMarch 28, 2023 | americanbankingnews.comARCA biopharma (NASDAQ:ABIO) Research Coverage Started at StockNews.comMarch 27, 2023 | americanbankingnews.comStockNews.com Begins Coverage on ARCA biopharma (NASDAQ:ABIO)March 28, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 19, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on ARCA biopharma (NASDAQ:ABIO)March 10, 2023 | msn.comCan Frankie Muniz Contend at Phoenix After His Impressive ARCA Debut?February 24, 2023 | finance.yahoo.comARCA biopharma Announces 2022 Financial Results and Provides Corporate UpdateFebruary 18, 2023 | foxnews.comFrankie Muniz finishes 11th in ARCA debut at Daytona International SpeedwayFebruary 14, 2023 | msn.comARCA gets funding for new 40-foot mobile clinic, helps end surge of drug overdose deaths in St. Louis regionMarch 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. January 11, 2023 | foxnews.comFrankie Muniz to race in ARCA Menards SeriesJanuary 11, 2023 | benzinga.comFRANKIE MUNIZ TAKES ON 2023 ARCA MENARDS SERIES CHAMPIONSHIP IN RETTE JONES RACING NO. 30 FORD MUSTANGJanuary 9, 2023 | msn.com‘Goya, Carrière and the Ghost of Buñuel’ Wins Uruguay’s ARCAJanuary 2, 2023 | msn.comFeaturing ‘Caravaggio,’ ‘Charlotte,’ ‘Dreaming Walls,’ Uruguay’s ARCA Kicks Off Second EditionDecember 19, 2022 | finance.yahoo.comJames Flynn Joins ARCA biopharma Board of DirectorsNovember 14, 2022 | finance.yahoo.comOne ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous yearOctober 29, 2022 | finanznachrichten.deARCA biopharma, Inc.: ARCA biopharma Announces Third Quarter 2022 Financial ResultsOctober 28, 2022 | finance.yahoo.comARCA biopharma Announces Third Quarter 2022 Financial ResultsOctober 13, 2022 | msn.comMother, daughter set to compete in ARCA West race in Las VegasOctober 9, 2022 | foxnews.comARCA race ends with tempers flaring between Sammy Smith, Jesse LoveOctober 7, 2022 | msn.comHow to Watch NASCAR, Formula 1, ARCA and Everything Else in Racing This Weekend, October 8-9September 20, 2022 | seekingalpha.comABIO ARCA biopharma, Inc.September 15, 2022 | foxnews.comARCA driver Toni Breidinger becomes Victoria's Secret model: 'Little me is crying'September 14, 2022 | msn.comNASCAR returns to Milwaukee Mile with Craftsman Truck and ARCA seriesSeptember 11, 2022 | msn.comCorey Heim bows out of ARCA series with Kansas Speedway winSeptember 4, 2022 | msn.comDu Quoin State Fair ARCA Menards Series event postponed due to wet conditionsAugust 26, 2022 | tmcnet.comSESAMI WELCOMES GLOBAL LEADER ARCA AS IT STRENGTHENS ITS GLOBAL LEADERSHIP IN CASH AUTOMATION SOLUTIONSAugust 18, 2022 | msn.comHow to watch Watkins Glen ARCA Menards race: Time, TV channel, free live streamSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ABIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ABIO Company Calendar Last Earnings8/04/2021Today3/28/2023Next Earnings (Estimated)5/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABIO CUSIPN/A CIK907654 Webarcabio.com Phone(720) 940-2100Fax720-208-9261Employees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.39% Return on Assets-21.21% Debt Debt-to-Equity RatioN/A Current Ratio37.72 Quick Ratio37.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book0.72Miscellaneous Outstanding SharesN/AFree FloatN/AMarket Cap$29.97 million OptionableNot Optionable Beta1.47 Key ExecutivesMichael R. BristowPresident, Chief Executive Officer & DirectorThomas A. KeuerChief Operating OfficerC. Jeffrey DekkerChief Financial OfficerChristopher David OzeroffSecretary, Senior Vice President & General CounselSharon PerryVice President-Regulatory Affairs & QualityKey CompetitorsBiomericaNASDAQ:BMRANymox PharmaceuticalNASDAQ:NYMXOncoCyteNASDAQ:OCXTrinity BiotechNASDAQ:TRIBImmuCellNASDAQ:ICCCView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 14,578 shares on 2/15/2023Ownership: 0.101%Susquehanna International Group LLPSold 810,400 shares on 2/14/2023Ownership: 0.000%SG3 Management LLCSold 100,000 shares on 2/14/2023Ownership: 0.000%BML Capital Management LLCBought 858,256 shares on 2/13/2023Ownership: 5.956%Murchinson Ltd.Bought 50,593 shares on 2/10/2023Ownership: 0.351%View All Insider TransactionsView All Institutional Transactions ABIO Stock - Frequently Asked Questions How have ABIO shares performed in 2023? ARCA biopharma's stock was trading at $2.37 at the start of the year. Since then, ABIO stock has decreased by 12.7% and is now trading at $2.0691. View the best growth stocks for 2023 here. Are investors shorting ARCA biopharma? ARCA biopharma saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 226,300 shares, a decline of 7.1% from the February 28th total of 243,500 shares. Based on an average daily volume of 38,700 shares, the days-to-cover ratio is currently 5.8 days. Approximately 1.6% of the company's shares are short sold. View ARCA biopharma's Short Interest. When is ARCA biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023. View our ABIO earnings forecast. How were ARCA biopharma's earnings last quarter? ARCA biopharma, Inc. (NASDAQ:ABIO) released its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($2.37) by $2.03. What is Michael R. Bristow's approval rating as ARCA biopharma's CEO? 1 employees have rated ARCA biopharma Chief Executive Officer Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among the company's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ARCA biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP). What is ARCA biopharma's stock symbol? ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO." Who are ARCA biopharma's major shareholders? ARCA biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (5.96%), Murchinson Ltd. (0.35%), Susquehanna International Group LLP (0.00%), Jane Street Group LLC (0.10%), SG3 Management LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Christopher David Ozeroff, Fund Lp Funicular and Robert E Conway. View institutional ownership trends. How do I buy shares of ARCA biopharma? Shares of ABIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ARCA biopharma's stock price today? One share of ABIO stock can currently be purchased for approximately $2.07. How much money does ARCA biopharma make? ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $29.97 million. The biopharmaceutical company earns $-9,930,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. How can I contact ARCA biopharma? ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for the company is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2100, via email at derek.cole@arcabio.com, or via fax at 720-208-9261. This page (NASDAQ:ABIO) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.